Indoco's Goa Plant II & III clears USFDA inspection
The USFDA inspected Indoco’s Sterile facility (Plant II) and Solid Dosages facility (Plant III) situated at L-32/33/34 Verna Industrial Estate, Goa from November 14-21, 2018. The inspection concluded with Indoco receiving two minor observations, none of which are repeat. This facility had received a Warning Letter from the USFDA in March 2017.
The company is in the process of responding to the observations within the stipulated time of 15 days. The EIR will be issued by the USFDA subsequently.
“This positive development will now pave the way for approval of our pending ANDAs with consequent boost to revenues from the US market. Indoco is committed to its philosophy of highest quality in manufacturing, operations, systems integrity and cGMP culture,” said Ms. Aditi Kare Panandikar, Managing Director of Indoco Remedies Ltd.
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
2026-07-25
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
EPA Pressures Minnesota to Tackle Nitrate Threat in Drinking Water
-
FDA Proposes Nationwide Ban on Brominated Vegetable Oil (BVO) in Food Additives, Continues Safety Assessment of Chemicals
-
USDA-FSIS Initiates Year-Long Survey of Dioxins in Cattle, Swine, and Catfish Starting November
-
New Advance Notification Guidelines for Imported Foods Released by the United States
-
The world's first octreotide capsule was approved by the FDA!
Recommend Reading
-
Styrene-Butadiene Rubber Market Prices Narrowly Fluctuate
-
Shuntung Rubber Market Prices Fluctuate and Consolidate
-
Bismutat Explained: Properties, Uses, and Comparison with Bismuth
-
U.S.-Iran Conflict Reignites, International Crude Oil Surges Over 9% in a Single Day
-
September Adipic Acid Market Fluctuates and Declines